Sanofi nears $11.4 billion deal for Bioverativ: source
French drugmaker Sanofi is close to acquiring biotechnology company Bioverativ for $105 a share, valuing the maker of hemophilia drugs at about $11.4 billion, according to a person familiar with the matter. The deal could be announced as soon as Monday ...
Sanofi set to buy Bioverativ for more than $11.5 billion: WSJ
Sanofi Nears Deal to Buy Hemophilia Drugmaker Bioverativ for More Than $11.5 Billion
Financial Comparison: Cytokinetics (CYTK) and Bioverativ (NASDAQ:BIVV)